CHEUNG ANTHONY TZEYEW 4

What Happened

• Anthony Cheung, Chief Scientific Officer of enGene Holdings, was granted a derivative award of 195,000 shares on January 30, 2026. The award was recorded at a $0.00 acquisition price (no cash paid) and is reported as a derivative security on the Form 4. This is an equity grant/award rather than a purchase or sale.

Key Details

• Transaction date: 2026-01-30; Form 4 filed: 2026-02-03
• Shares/units granted: 195,000; reported acquisition price: $0.00 (derivative)
• Vesting: Footnote states the option/award vests monthly in substantially equal amounts over 48 months, subject to continued service
• Shares owned after transaction: Not disclosed in the filing
• Transaction code: A (grant/award); derivative designation noted in the filing
• No indication in the filing that this was an exercise, sale, gift, or part of a 10b5-1 plan

Context

• This was a standard equity award/retention grant to an executive; no cash changed hands at grant. Because it’s a derivative award with a multi-year monthly vesting schedule, its economic benefit depends on future vesting and any future exercise/sale. The filing does not state immediate sales or tax-withholding dispositions.